ClinicalTrials.gg
Not yet recruitingNCT03556709Updated Jun 14, 2018

Walking Ankle Robot for Foot Drop in Aging and Disabled Populations: A Demonstration Project

An interventional study of Treadmill Ankle Robot Training in Foot Drop, Peripheral Nervous System Diseases and Gait Disorders, Neurologic, sponsored by Baltimore VA Medical Center. Not yet recruiting. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2018-06-14.

Sponsored by Baltimore VA Medical Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 88 Years
Sex
All
01

Study summary

The purpose of this research study is to test the utility of an ankle robot, when used during treadmill walking, in people with ankle weakness and foot drop from a peripheral nervous system injury due to neuromuscular or orthopedic injury.

Read the detailed description

Many individuals with central nervous system (CNS) injuries (e.g., a stroke) or peripheral nervous system (PNS) injuries (e.g., peroneal nerve injury, neuropathy, radiculopathy, and/or musculoskeletal injury) that affect their ankle movement have residual impairments that affect their walking and balance. These impairments include the disability "foot drop," which increases the risk for falling.

This study will focus on PNS injuries that cause foot drop.

Current therapy to address foot drop is limited primarily to the use of ankle foot orthoses (braces) that help keep the foot from hitting the ground to prevent falling. Also, some individuals with foot drop use functional electrical stimulation to the leg nerve to lift the foot. Regardless, none of these, or other existing, methods to address foot drop cures or even improves significantly the underlying neurological deficit behind this disability. Braces improve walking safety only while they are worn, and functional electrical stimulation does not work when it is turned off, or when the nerve has been severely damaged. Thus, the increased fall risk due to foot drop is generally considered life-long and incurable.

The investigators have developed a shoe-interfaced ankle robot with an adaptive control system, to assist an individual with ankle movement only as needed. Data from the investigators' previous studies on foot drop due to stroke show great promise for this ankle robot as a new rehabilitation tool for invididuals with foot drop, when used during treadmill walking. The investigators would like to utilize our findings from these stroke studies in learning how they can be used for PNS-related foot drop.

02

Conditions studied

  • Foot Drop
  • Peripheral Nervous System Diseases
  • Gait Disorders, Neurologic
  • Mobility Limitation
03

In context

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

This study's planned enrollment of 100 is above the median of 57 across 359 interventional studies indexed under Peripheral Nervous System Diseases.

Browse Peripheral Nervous System Diseases studies →

Lead sponsor

Baltimore VA Medical Center is the lead sponsor of 19 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women, aged 18 to 88 years
  2. Chronic foot drop and ankle weakness in one leg from a peripheral nervous system injury due to a neuromuscular or orthopedic injury
  3. Ability to walk 10 meters and arise from a chair with no human assistance (but usage of usual assistive device[s] is permitted)

Exclusion criteria

Exclusion Criteria:

  1. Cardiac history of (a) unstable angina; (b) recent (less than 3 months) myocardial infarction, congestive heart failure ( category II); and/or (c) hemodynamically significant valvular dysfunction
  2. Hypertension that is a for a bout of walking training (greater than 160/100 mmHg on two assessments)
  3. Medical history of (a) recent hospitalization (less than 3 months) for severe medical disease; (b) symptomatic peripheral arterial occlusive disease; (c) orthopedic or chronic pain conditions that significantly alter gait function; (d) pulmonary or renal failure; and/or (e) active cancer
  4. Current participation in orthopedic or rehabilitation medical programs
  5. Active deep venous thrombosis
  6. Distal paretic leg skin lesions, infections, or soft tissue inflammation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Treadmill Ankle Robot Training

    Device: Treadmill Ankle Robot Training

Interventions

  • DeviceTreadmill Ankle Robot Training

    This intervention employs the use of an adaptive ankle robot control system, during treadmill walking, over a 6-week intervention period.

06

What researchers measure

Primary outcomes

  1. Gait velocity during self-selected overground walking

    cm/sec

    Time frame: Change from baseline to: post-6 weeks of training, and 6 weeks after completion of training

  2. Peak dorsiflexion angle during swing phase of gait

    degrees; extent of ankle dorsiflexion to enable foot clearance

    Time frame: Change from baseline to: post-6 weeks of training, and 6 weeks after completion of training

  3. Ankle dorsiflexion-plantarflexion range of motion

    degrees

    Time frame: Change from baseline to: post-6 weeks of training, and 6 weeks after completion of training

  4. Postural sway areas during quiet standing

    cm\^2; extent of postural deviations to assess static postural control

    Time frame: Change from baseline to: post-6 weeks of training, and 6 weeks after completion of training

  5. Ratio of asymmetric loading in quiet standing

    ratio of Newtons of force per each leg (paretic/nonparetic) while standing quietly

    Time frame: Change from baseline to: post-6 weeks of training, and 6 weeks after completion of training

  6. Push-off forces during gait initiation

    Newtons; magnitude of forward ground reaction forces.

    Time frame: Change from baseline to: post-6 weeks of training, and 6 weeks after completion of training

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2018; primary completion for Dec 2028, 124 months later.

Of 122 non-industry interventional studies with no phase under Peripheral Nervous System Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 124 months is above that.

Counting every sponsor, half of 132 studies reached it within 25 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2018
First posted
Jun 14, 2018
StartEst.
Aug 1, 2018
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jun 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03556709
Lead sponsor
Baltimore VA Medical Center
Responsible party
Charlene Elaine Hafer-Macko, M.D. (Associate Professor of Neurology, Baltimore VA Medical Center) — Principal investigator
First posted
Jun 14, 2018
Start date
Aug 1, 2018 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 14, 2018

Study contacts

Kate C. Flores
Contact
kate.flores@va.gov
(410) 637-3242
Charlene E. Hafer-Macko, M.D.
principal investigator · Baltimore VA Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion